U.S. Stocks Rise, Nasdaq Gains Over 200 Points
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Source: Benzinga
- Nasdaq Performance: The Nasdaq Composite rose over 200 points on Friday, closing at 22,917.24, indicating strong demand for tech stocks and potentially reflecting investor optimism about future economic recovery.
- PPL Corporation Earnings: PPL Corporation reported mixed Q4 fiscal 2025 results with operating revenue of $2.27 billion, falling short of the $2.42 billion consensus estimate, although adjusted EPS of 41 cents met analyst expectations, highlighting challenges in revenue growth.
- Dividend Increase: PPL raised its quarterly dividend by 4.6% to 28.50 cents per share, demonstrating confidence in future cash flows and a commitment to shareholder returns amidst fluctuating earnings.
- Market Dynamics: On Friday, communication services stocks gained 2.3%, while healthcare stocks fell by 0.7%, indicating performance disparities across sectors that may influence investors' asset allocation strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 66.550
Low
38.00
Averages
60.86
High
83.71
Current: 66.550
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Grail Shares Rise 11.5% Post-ASCO Conference Amid Mixed Results
- Stock Price Surge: Grail's shares rose by 11.5% to $6.13 in early trading, indicating that investors capitalized on a price dip following the ASCO conference, although the prior strong performance led some to take profits.
- Mixed Data Presentation: Despite showcasing data for its multi-cancer early detection test Galleri at ASCO, Grail failed to provide compelling evidence for FDA approval and insurance coverage, leaving investors cautious about future prospects.
- Trial Results Impact: The Galleri test did not meet its primary endpoint in a 142,000-person trial conducted by the NHS, failing to significantly reduce late-stage cancer detection rates, which raises concerns among investors regarding its market viability.
- Sensitivity Metrics: The Galleri test demonstrated a sensitivity of 69.8% for 12 cancers responsible for two-thirds of cancer deaths in the U.S. trial, but this alone is insufficient for insurance coverage, making future FDA approval a critical factor.
See More
Grail Class Action Lawsuit Initiated Over Stock Misrepresentation
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL), representing stock purchasers from May 13, 2025, to February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by its executives.
- False Statement Allegations: The lawsuit claims that Grail falsely asserted its NHS-Galleri trial would significantly reduce late-stage cancer rates, yet the actual results revealed no statistically significant reduction, causing the stock price to plummet over 50% on February 19, 2026.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing other investors in the lawsuit and selecting their preferred law firm for representation.
- Law Firm Strength: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years, highlighting its significant strength and influence in the securities class action landscape.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: GRAIL, Inc. faces a class action lawsuit for allegedly providing misleading information to investors between May 13, 2025, and February 19, 2026, concealing the true status of its NHS-Galleri trial, which has resulted in significant investor losses.
- Trial Results Disclosure: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, indicating that the trial's design and duration were insufficient to support the achievement of its primary endpoint, directly impacting investor confidence.
- Stock Price Plunge: Following the trial results announcement, GRAIL's stock price plummeted from $101.53 per share on February 19, 2026, to $50.21 per share on February 20, 2026, reflecting a dramatic decline of approximately 50.55%, showcasing the market's extreme pessimism regarding the company's future.
- Investor Action Call: The law firm Levi & Korsinsky urges GRAIL shareholders to apply to be lead plaintiffs by the August 4, 2026 deadline to seek compensation for losses caused by corporate misrepresentations, emphasizing their extensive experience and successful track record in securities litigation.
See More
Grail Shares Surge 31.6% on ASCO Presentation Optimism
- Significant Stock Surge: Grail's shares surged by 31.6% in May, reaching $5.42 per share, as market optimism grew around its presentation at the American Society of Clinical Oncology (ASCO) meeting, which is expected to bolster the case for FDA approval of the Galleri test and enhance insurance coverage.
- Clinical Trial Setbacks: Despite the Galleri test's failure to meet primary endpoints in a three-year trial conducted by the NHS, management highlighted a substantial increase in early-stage cancers among 12 specified deadly cancer types, indicating potential clinical significance and a favorable trend in detection rates.
- FDA Collaboration Strategy: Grail plans to continue working with the FDA to secure approval for the Galleri test and present detailed results from the NHS trial at ASCO, aiming to strengthen the case for FDA approval and persuade insurers to cover the test.
- Future Prospects: Management aims to obtain NHS approval for follow-up trials by next summer, emphasizing the critical importance of early-stage cancer diagnosis in improving survival rates, which could further enhance market acceptance of the Galleri test.
See More
Grail's Stock Pullback Yet Promising Future Ahead
- Stock Fluctuation: Grail's stock reached a record high of $116.06 in January 2024, reflecting a 732% increase from its $13.95 opening price, but currently trades around $68, indicating a disparity between market expectations and reality regarding its Galleri blood test.
- Revenue Growth: Despite the lack of FDA approval for Galleri, Grail sells the test for $749 to $949 to affluent customers, with revenue projected to rise from $93 million in 2023 to $147 million by 2025, demonstrating strong market demand.
- Clinical Trial Challenges: Grail's critical NHS trial failed to meet its primary endpoint; however, Galleri users showed fewer late-stage cancer detections, suggesting potential in early cancer detection, though FDA approval may take years.
- Future Outlook: Grail anticipates a revenue increase of 22%-32% for 2024, with analysts forecasting annual growth rates of 22%-27% from 2026 to 2028, and while it trades at 15 times this year's sales, the potential for significant growth exists if Galleri receives full FDA approval.
See More
Grail's Stock Drops 16% Following ASCO Presentation
- Significant Stock Decline: Grail's stock fell 16% to $62.93, with a market cap of $3.1 billion, indicating a negative market reaction to the data presented at the ASCO Annual Meeting, undermining investor confidence in FDA approval and insurer adoption.
- Trial Results Mixed: The Galleri test failed to significantly reduce late-stage cancer detection rates in a three-year trial with the NHS, although management claimed a 'substantial and clinically meaningful reduction' in Stage IV diagnoses compared to standard care, yet the market remained unimpressed.
- Sensitivity Data Insights: The Galleri test detected cancer in 287 participants, with 173 later diagnosed, resulting in a 60.3% positive result confirmation rate; however, the overall sensitivity for all cancers was only 39.3%, raising concerns about its effectiveness among investors.
- Investor Opportunity: Despite the aggressive market sell-off, investors might consider focusing on the 69.8% sensitivity for the 12 key cancers detected by the Galleri test, suggesting that if insurers share this perspective, today's decline could present a buying opportunity.
See More
Grail Shares Rise 11.5% Post-ASCO Conference Amid Mixed Results
- Stock Price Surge: Grail's shares rose by 11.5% to $6.13 in early trading, indicating that investors capitalized on a price dip following the ASCO conference, although the prior strong performance led some to take profits.
- Mixed Data Presentation: Despite showcasing data for its multi-cancer early detection test Galleri at ASCO, Grail failed to provide compelling evidence for FDA approval and insurance coverage, leaving investors cautious about future prospects.
- Trial Results Impact: The Galleri test did not meet its primary endpoint in a 142,000-person trial conducted by the NHS, failing to significantly reduce late-stage cancer detection rates, which raises concerns among investors regarding its market viability.
- Sensitivity Metrics: The Galleri test demonstrated a sensitivity of 69.8% for 12 cancers responsible for two-thirds of cancer deaths in the U.S. trial, but this alone is insufficient for insurance coverage, making future FDA approval a critical factor.
See More
Grail Class Action Lawsuit Initiated Over Stock Misrepresentation
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL), representing stock purchasers from May 13, 2025, to February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by its executives.
- False Statement Allegations: The lawsuit claims that Grail falsely asserted its NHS-Galleri trial would significantly reduce late-stage cancer rates, yet the actual results revealed no statistically significant reduction, causing the stock price to plummet over 50% on February 19, 2026.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing other investors in the lawsuit and selecting their preferred law firm for representation.
- Law Firm Strength: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years, highlighting its significant strength and influence in the securities class action landscape.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: GRAIL, Inc. faces a class action lawsuit for allegedly providing misleading information to investors between May 13, 2025, and February 19, 2026, concealing the true status of its NHS-Galleri trial, which has resulted in significant investor losses.
- Trial Results Disclosure: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, indicating that the trial's design and duration were insufficient to support the achievement of its primary endpoint, directly impacting investor confidence.
- Stock Price Plunge: Following the trial results announcement, GRAIL's stock price plummeted from $101.53 per share on February 19, 2026, to $50.21 per share on February 20, 2026, reflecting a dramatic decline of approximately 50.55%, showcasing the market's extreme pessimism regarding the company's future.
- Investor Action Call: The law firm Levi & Korsinsky urges GRAIL shareholders to apply to be lead plaintiffs by the August 4, 2026 deadline to seek compensation for losses caused by corporate misrepresentations, emphasizing their extensive experience and successful track record in securities litigation.
See More
Grail Shares Surge 31.6% on ASCO Presentation Optimism
- Significant Stock Surge: Grail's shares surged by 31.6% in May, reaching $5.42 per share, as market optimism grew around its presentation at the American Society of Clinical Oncology (ASCO) meeting, which is expected to bolster the case for FDA approval of the Galleri test and enhance insurance coverage.
- Clinical Trial Setbacks: Despite the Galleri test's failure to meet primary endpoints in a three-year trial conducted by the NHS, management highlighted a substantial increase in early-stage cancers among 12 specified deadly cancer types, indicating potential clinical significance and a favorable trend in detection rates.
- FDA Collaboration Strategy: Grail plans to continue working with the FDA to secure approval for the Galleri test and present detailed results from the NHS trial at ASCO, aiming to strengthen the case for FDA approval and persuade insurers to cover the test.
- Future Prospects: Management aims to obtain NHS approval for follow-up trials by next summer, emphasizing the critical importance of early-stage cancer diagnosis in improving survival rates, which could further enhance market acceptance of the Galleri test.
See More
Grail's Stock Pullback Yet Promising Future Ahead
- Stock Fluctuation: Grail's stock reached a record high of $116.06 in January 2024, reflecting a 732% increase from its $13.95 opening price, but currently trades around $68, indicating a disparity between market expectations and reality regarding its Galleri blood test.
- Revenue Growth: Despite the lack of FDA approval for Galleri, Grail sells the test for $749 to $949 to affluent customers, with revenue projected to rise from $93 million in 2023 to $147 million by 2025, demonstrating strong market demand.
- Clinical Trial Challenges: Grail's critical NHS trial failed to meet its primary endpoint; however, Galleri users showed fewer late-stage cancer detections, suggesting potential in early cancer detection, though FDA approval may take years.
- Future Outlook: Grail anticipates a revenue increase of 22%-32% for 2024, with analysts forecasting annual growth rates of 22%-27% from 2026 to 2028, and while it trades at 15 times this year's sales, the potential for significant growth exists if Galleri receives full FDA approval.
See More
Grail's Stock Drops 16% Following ASCO Presentation
- Significant Stock Decline: Grail's stock fell 16% to $62.93, with a market cap of $3.1 billion, indicating a negative market reaction to the data presented at the ASCO Annual Meeting, undermining investor confidence in FDA approval and insurer adoption.
- Trial Results Mixed: The Galleri test failed to significantly reduce late-stage cancer detection rates in a three-year trial with the NHS, although management claimed a 'substantial and clinically meaningful reduction' in Stage IV diagnoses compared to standard care, yet the market remained unimpressed.
- Sensitivity Data Insights: The Galleri test detected cancer in 287 participants, with 173 later diagnosed, resulting in a 60.3% positive result confirmation rate; however, the overall sensitivity for all cancers was only 39.3%, raising concerns about its effectiveness among investors.
- Investor Opportunity: Despite the aggressive market sell-off, investors might consider focusing on the 69.8% sensitivity for the 12 key cancers detected by the Galleri test, suggesting that if insurers share this perspective, today's decline could present a buying opportunity.
See More
